Table of Contents Understanding Mounjaro and Its Gastrointestinal Effects Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities
Call Before Changing the Dose Do not increase, reduce or skip doses without speaking with the prescribing provider
Hb oxidation also occurs as a natural process, resulting from RBC aging [33], that is associated with metabolic degradation due to reduction in enzyme activity
Similar reasoning can be applied to most specialized diets, but it is important to undergo restricted diets only under supervision of a physician or nutritionist who is familiar with them
GHK-Cu, retinoids, vitamin C, and other active ingredients are layered on top of that foundation